Literature DB >> 9489797

Antenatal diagnosis of lethal skeletal dysplasias.

A E Tretter1, R C Saunders, C M Meyers, J S Dungan, K Grumbach, C C Sun, A B Campbell, E A Wulfsberg.   

Abstract

Lethal skeletal dysplasias (LSD) are a heterogeneous group of rare but important genetic disorders characterized by abnormal growth and development of bone and cartilage. We describe the diagnosis and outcome of 29 cases of lethal skeletal dysplasias evaluated between January 1989 and December 1996 at the University of Maryland Medical Center and the Ultrasound Institute of Baltimore. Two cases presented at delivery with no prenatal care while the remaining 27 cases were identified by antenatal sonography. Final diagnoses included thanatophoric dysplasia (14), osteogenesis imperfecta, type II (6), achondrogenesis (2), short rib syndromes (3), campomelic syndrome (2), atelosteogenesis (1), and no evidence of a skeletal dysplasia (1). Twenty out of 27 pregnancies were terminated with an average at detection of 21.6 weeks. The other 7 pregnancies that went on to deliver had an average age at detection of 29.2 weeks. Fetal abnormalities in the terminated pregnancies were identified at a significantly earlier gestational age (P = 0.0016) than the pregnancies that continued. While the identification of LSD by sonography was excellent (26/27), only 13/27 (48%) were given an accurate specific antenatal diagnosis. In 8/14 (57%) cases with an inaccurate or nonspecific diagnosis there was a significant or crucial change in the genetic counseling. Thus, while antenatal sonography is an excellent method for discovering LSD, clinical examination, radiographs, and autopsy are mandatory for making a specific diagnosis.

Entities:  

Mesh:

Year:  1998        PMID: 9489797

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  13 in total

1.  Camptomelic dysplasia: prenatal diagnosis by ultrasound.

Authors:  Gupta Natasha; Rajeev Ghai; Dheeraj Shah; P S Kiran
Journal:  Skeletal Radiol       Date:  2005-09-20       Impact factor: 2.199

2.  Disruption of Trip11 in cranial neural crest cells is associated with increased ER and Golgi stress contributing to skull defects in mice.

Authors:  Hiroyuki Yamaguchi; Matthew D Meyer; Li He; Yoshihiro Komatsu
Journal:  Dev Dyn       Date:  2022-02-18       Impact factor: 2.842

3.  Evaluation of prenatal-onset osteochondrodysplasias by ultrasonography: a retrospective and prospective analysis.

Authors:  Deborah Krakow; Yasemin Alanay; Lauren P Rimoin; Victoria Lin; William R Wilcox; Ralph S Lachman; David L Rimoin
Journal:  Am J Med Genet A       Date:  2008-08-01       Impact factor: 2.802

4.  Deletion of the GATA domain of TRPS1 causes an absence of facial hair and provides new insights into the bone disorder in inherited tricho-rhino-phalangeal syndromes.

Authors:  Talat H Malik; Dietrich Von Stechow; Roderick T Bronson; Ramesh A Shivdasani
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

5.  Foetal radiography for suspected skeletal dysplasia: technique, normal appearances, diagnostic approach.

Authors:  Alistair D Calder; Amaka C Offiah
Journal:  Pediatr Radiol       Date:  2014-08-31

Review 6.  A guide to the recognition of skeletal disorders in the fetus.

Authors:  Rita L Teele
Journal:  Pediatr Radiol       Date:  2006-03-09

7.  Spectrum of severe skeletal dysplasias in North India.

Authors:  Ratna D Puri; Seema Thakur; I C Verma
Journal:  Indian J Pediatr       Date:  2007-11       Impact factor: 1.967

8.  De novo achondroplasia causing four consecutive unsuccessful pregnancies: a case report.

Authors:  Anthony Osita Igwegbe; George Uchenna Eleje; Ikechukwu Francis Ugwueke
Journal:  J Med Case Rep       Date:  2012-08-30

Review 9.  Advances in evaluating the fetal skeleton.

Authors:  Ann-Edwidge Noel; Richard N Brown
Journal:  Int J Womens Health       Date:  2014-05-13

10.  Guidelines for the prenatal diagnosis of fetal skeletal dysplasias.

Authors:  Deborah Krakow; Ralph S Lachman; David L Rimoin
Journal:  Genet Med       Date:  2009-02       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.